Kytopen and Bio-Techne Collaborate to Advance Cell Therapy Manufacturing
Kytopen Corp., known for its innovative continuous flow cellular engineering technologies, has recently partnered with Bio-Techne Corporation (NASDAQ: TECH) to streamline the manufacturing process of cell therapies. This collaboration is designed to leverage both companies' strengths in developing cutting-edge gene delivery solutions that enhance the efficiency of advanced cell therapies.
Innovative Technologies for Efficient Gene Delivery
At the core of this collaboration is the TcBuster™ system, which facilitates the integration of large, multigene cargos into cells efficiently and swiftly. This non-viral system offers several advantages over traditional approaches, particularly lentivirus-based methods, by maintaining high editing efficiency and a favorable insertion profile. The TcBuster technology provides researchers with a powerful tool for developing diverse immune cell types, including those that are non-dividing or particularly sensitive to cell stress.
Flowfect™ Technology: A Game Changer
Coupled with the TcBuster system, Bio-Techne's Flowfect™ technology enhances cellular processing capabilities. This unique platform combines mechanical, electrical, and chemical mechanisms, allowing researchers to adjust parameters to optimize transfection efficiency and cell viability. Remarkably, this continuous flow technology enables the processing of vast numbers of cells within minutes, a feat that is crucial for the rapid development of clinical-grade cellular therapies.
Transformative Impact on Advanced Cell Therapies
The partnership aims to deliver high gene insertion efficiencies and cell viability, which are crucial metrics in the development of high-quality cell therapies. By utilizing the combined expertise and technology from Kytopen and Bio-Techne, developers can expect more effective and streamlined manufacturing processes, facilitating faster progress from research stages to clinical application.
Implications for Future Research
Data stemming from this collaboration will be presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting. This event will showcase the innovative results and possibilities which arise from the partnership, underlining the commitment of both companies to drive forward the field of cell therapy development.
About Kytopen and Bio-Techne
Kytopen, located in Cambridge, is at the forefront of non-viral cell engineering, enabling researchers to produce engineered cells in unparalleled volumes and timeframes. Their vision is to not only boost cell therapy effectiveness but also to ensure that such advanced techniques can be reliably and sustainably incorporated into everyday medical practices. Bio-Techne, headquartered in Minneapolis, provides essential life science tools that support research and clinical diagnostics globally, facilitating drug discovery and improving diagnostic accuracy.
Both companies share a dedication to advancing healthcare and offer a robust partnership that aims to improve access to effective cell therapies. Their collaboration stands to benefit numerous patients by enhancing the speed and efficiency of cell therapy development.
Frequently Asked Questions
What is the focus of the collaboration between Kytopen and Bio-Techne?
The collaboration aims to improve cell therapy manufacturing by utilizing advanced gene delivery technologies that allow for more efficient and effective cell processing.
What technologies are being used in this partnership?
The TcBuster™ system and Flowfect™ technology are the key components that enhance the gene editing and cell processing workflows.
Where will the data from this collaboration be presented?
The data will be showcased at the ISCT Annual Meeting, highlighting the advancements achieved through this partnership.
What makes the TcBuster system advantageous?
The TcBuster system offers a non-viral approach to gene editing, allowing for the simultaneous delivery of multiple genes with high efficiency and safety.
How does the Flowfect technology contribute to cell therapy manufacturing?
Flowfect technology enables the processing of large volumes of cells very quickly, while ensuring high cell viability, which is crucial for effective therapy development.
